[go: up one dir, main page]

AR089320A1 - Cepa de lactobacillus mucosae - Google Patents

Cepa de lactobacillus mucosae

Info

Publication number
AR089320A1
AR089320A1 ARP120104813A ARP120104813A AR089320A1 AR 089320 A1 AR089320 A1 AR 089320A1 AR P120104813 A ARP120104813 A AR P120104813A AR P120104813 A ARP120104813 A AR P120104813A AR 089320 A1 AR089320 A1 AR 089320A1
Authority
AR
Argentina
Prior art keywords
strain
lactobacillus mucosae
mucosae strain
intestinal barrier
lactobacillus
Prior art date
Application number
ARP120104813A
Other languages
English (en)
Inventor
Degivry Marie
Christine-Smokvina Tamara
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of AR089320A1 publication Critical patent/AR089320A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cepa de Lactobacillus mucosae que tiene la capacidad de disminuir la permeabilidad de la barrera intestinal. Esta cepa es útil, en especial, para el alivio de disfunciones de la barrera intestinal. Método para obtener la cepa. Composición que contiene la cepa. Método para obtener la composición. La cepa para utilizar como medicamento
ARP120104813A 2011-12-21 2012-12-19 Cepa de lactobacillus mucosae AR089320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/055876 WO2013093561A1 (en) 2011-12-21 2011-12-21 Novel strain of lactobacillus mucosae

Publications (1)

Publication Number Publication Date
AR089320A1 true AR089320A1 (es) 2014-08-13

Family

ID=45529150

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104813A AR089320A1 (es) 2011-12-21 2012-12-19 Cepa de lactobacillus mucosae

Country Status (9)

Country Link
US (1) US9297049B2 (es)
EP (1) EP2794930B1 (es)
CN (1) CN104053767B (es)
AR (1) AR089320A1 (es)
BR (1) BR112014015527B1 (es)
ES (1) ES2598552T3 (es)
PL (1) PL2794930T3 (es)
RU (1) RU2606770C2 (es)
WO (1) WO2013093561A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2017001272A1 (es) * 2017-05-17 2018-03-16 Univ San Sebastian Compuesto antitumoral inmuno estimulante derivado de un probiótico; método de obtención, composiciones farmacéuticas que lo contienen y usos de las mismas
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
EP3870691A4 (en) * 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
CN109486722B (zh) * 2018-12-26 2020-08-04 江南大学 一株具有抗流感能力的粘膜乳杆菌及其应用
CN112877231B (zh) * 2019-11-29 2023-06-23 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 具有抑菌和抗氧化活性的乳酸菌及其应用
CN111440740B (zh) * 2020-04-02 2021-01-12 盐城工学院 一种粘膜乳杆菌及其在污水脱硫中的应用
CA3179561A1 (en) * 2020-04-08 2021-10-14 Megmilk Snow Brand Co., Ltd. Composition for improving gut microbiota
CN115786175B (zh) * 2022-09-30 2023-12-08 广东省农业科学院动物卫生研究所 一株粘膜乳杆菌及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
IT1398875B1 (it) * 2010-03-03 2013-03-21 Italstarter S R L Composizioni contenti l. mucosae per uso medico.
WO2011148220A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance

Also Published As

Publication number Publication date
BR112014015527A8 (pt) 2017-07-04
BR112014015527A2 (pt) 2017-06-13
EP2794930B1 (en) 2016-07-27
US20140328802A1 (en) 2014-11-06
BR112014015527B1 (pt) 2021-06-22
ES2598552T3 (es) 2017-01-27
CN104053767B (zh) 2016-10-12
PL2794930T3 (pl) 2017-03-31
EP2794930A1 (en) 2014-10-29
WO2013093561A1 (en) 2013-06-27
RU2606770C2 (ru) 2017-01-10
US9297049B2 (en) 2016-03-29
CN104053767A (zh) 2014-09-17
RU2014129803A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
AR089320A1 (es) Cepa de lactobacillus mucosae
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CR20150370A (es) Compuestos antivirales
CL2012002859A1 (es) Metodo para reducir el peso de un sujeto que comprende el uso de un modulador antioxidante de la inflamacion.
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2014003534A1 (es) Metodo para reducir el riesgo de un evento cardiovascular en un sujeto en terapia con estatina.
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
AR089993A1 (es) Macrociclos peptidomimeticos
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
UY33735A (es) Compuestos antivirales
IN2012DN06714A (es)
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
GT201400101A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
UY34681A (es) Un proceso para mejorar el aceite de la pirólisis, aceite de pirólisis tratado y su uso.
CL2014003565A1 (es) Uso de 2-metileno-19-nor-(20s)-1alpha,25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
CL2013003487A1 (es) Uso de un compuesto derivado de fosforamidato de nucleosido para tratar la fiebre dengue y compuestos especificos.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.

Legal Events

Date Code Title Description
FG Grant, registration